NYSE: LYB
LyondellBasell Industries N.V.CIK 0001489393 · SIC 2860 · Industrial Organic Chemicals
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (HPQ 10-Q) is open in full — no account needed.
LyondellBasell reports Q2 net income of $559M on margin expansion from supply disruptions
5 material changes detected. Sign up free to read the summary.
Summary not yet generated.
Partner
Trade LYB commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
LyondellBasell cuts receivables facility by $200M, extends term to June 2027
3 material changes detected. Sign up free to read the summary.
LyondellBasell shareholders authorize $3.4B+ share buyback, expand equity plan by 8M shares
4 material changes detected. Sign up free to read the summary.
LyondellBasell completes European asset sale to AEQUITA, reports Q1 2026 earnings
3 material changes detected. Sign up free to read the summary.
revenue $7.20B, net income $125.0M. LyondellBasell completes European asset sale, cuts dividend, sees Middle East disruption boost
5 material changes detected. Sign up free to read the summary.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed Jul 31, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Consolidated Statements of Operations (Unaudited)
| Description | Q2 ended Jun 30, 2026 | Q2 ended Jun 30, 2025 |
|---|---|---|
| Revenue: | ||
| Total revenue / net sales | 9,177 | 7,658 |
| Cost of revenue / cost of sales | 7,139 | 6,871 |
| Operating expenses: | ||
| Research and development | 34.0 | 35.0 |
| Selling, general and administrative | 387.0 | 435.0 |
| Impairment charges | 74.0 | 32.0 |
| Total operating expenses | 7,634 | 7,373 |
| Operating income | 1,543 | 285.0 |
| Interest expense | 138.0 | 118.0 |
| Other income/(expense), net | 56.0 | 29.0 |
| Income before income taxes | 808.0 | 224.0 |
| Income tax expense/(benefit) | 236.0 | 69.0 |
| Income from continuing operations | 572.0 | 155.0 |
| Discontinued operations, net of tax | (13.0) | (40.0) |
| Net income | 559.0 | 115.0 |
| Basic earnings per share | 1.71 | 0.34 |
| Diluted earnings per share | 1.71 | 0.34 |
Consolidated Balance Sheets
Millions of dollars
| Description | June 30, 2026 | December 31, 2025 |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | 2,630 | 3,443 |
| Restricted cash | 10 | 6 |
| Accounts receivable: | ||
| Trade, net | 3,754 | 2,362 |
| Related parties | 214 | 155 |
| Inventories | 4,079 | 3,533 |
| Prepaid expenses and other current assets | 978 | 612 |
| Assets held for sale | — | 757 |
| Total current assets | 11,665 | 10,868 |
| Operating lease assets | 1,498 | 1,514 |
| Property, plant and equipment | 26,026 | 25,802 |
| Less: Accumulated depreciation | (10,339) | (9,969) |
| Property, plant and equipment, net | 15,687 | 15,833 |
| Equity investments | 3,875 | 3,963 |
| Goodwill | 705 | 708 |
| Intangible assets, net | 394 | 450 |
| Other assets | 658 | 667 |
| Total assets | 34,482 | 34,003 |
| Millions of dollars, except shares and par value data | ||
| LIABILITIES, REDEEMABLE NON-CONTROLLING INTERESTS AND EQUITY | ||
| Current liabilities: | ||
| Current maturities of long-term debt | 1,461 | 588 |
| Short-term debt | 234 | 226 |
| Accounts payable: | ||
| Trade | 2,738 | 2,250 |
| Related parties | 495 | 444 |
| Accrued and other current liabilities | 2,179 | 1,956 |
| Liabilities held for sale | — | 665 |
| Total current liabilities | 7,107 | 6,129 |
| Long-term debt | 11,215 | 12,124 |
| Operating lease liabilities | 1,310 | 1,327 |
| Other liabilities | 1,704 | 1,900 |
| Deferred income taxes | 2,352 | 2,316 |
| Commitments and contingencies | ||
| Redeemable non-controlling interests | 114 | 114 |
| Shareholders’ equity: | ||
| Ordinary shares, €0.04 par value, 1,275 million shares authorized, 323,004,034 and 322,084,769 shares outstanding, respectively | 19 | 19 |
| Additional paid-in capital | 6,130 | 6,148 |
| Retained earnings | 7,044 | 6,812 |
| Accumulated other comprehensive loss | (1,022) | (1,310) |
| Treasury stock, at cost, 17,418,464 and 18,337,729 ordinary shares, respectively | (1,500) | (1,587) |
| Total Company share of shareholders’ equity | 10,671 | 10,082 |
| Non-controlling interests | 9 | 11 |
| Total equity | 10,680 | 10,093 |
| Total liabilities, redeemable non-controlling interests and equity | 34,482 | 34,003 |
Consolidated Statements of Cash Flows
Millions of dollars
| Description | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net income | 684 | 292 |
| Adjustments to reconcile net income to net cash provided by (used in) operating activities: | ||
| Depreciation and amortization | 689 | 655 |
| Impairments | 89 | 32 |
| Amortization of debt-related costs | 6 | 5 |
| Share-based compensation | 66 | 55 |
| Equity investments— | ||
| Equity income | (52) | (8) |
| Distributions of earnings, net of tax | 13 | 18 |
| Deferred income tax benefit | (48) | (30) |
| Loss on sale of business | 734 | — |
| Changes in assets and liabilities that provided (used) cash: | ||
| Accounts receivable | (1,692) | (81) |
| Inventories | (521) | (85) |
| Accounts payable | 721 | (433) |
| Other, net | (206) | (648) |
| Net cash provided by (used in) operating activities | 483 | (228) |
| Cash flows from investing activities: | ||
| Expenditures for property, plant and equipment | (539) | (1,022) |
| Cash contribution to disposed businesses | (310) | — |
| Proceeds from settlement of net investment hedges | — | 284 |
| Payments for settlement of net investment hedges | — | (234) |
| Other, net | 55 | 38 |
| Net cash used in investing activities | (794) | (934) |
| Cash flows from financing activities: | ||
| Repurchases of Company ordinary shares | — | (201) |
| Dividends paid common stock | (448) | (878) |
| Issuance of long-term debt | — | 499 |
| Payments of debt issuance costs | — | (5) |
| Other, net | (21) | (13) |
| Net cash used in financing activities | (469) | (598) |
| Effect of exchange rate changes on cash | (29) | 76 |
| Decrease in cash and cash equivalents and restricted cash | (809) | (1,684) |
| Cash and cash equivalents and restricted cash at beginning of period | 3,449 | 3,388 |
| Cash and cash equivalents and restricted cash at end of period | 2,640 | 1,704 |
Face scale: Millions of dollars. Amounts in millions USD; EPS as reported. Statements found on the EDGAR/iXBRL face print as filed; the rest are presentation-friendly mappings of filer XBRL tags. Use EDGAR for interactive notes and detail. Interactive statements & notes on EDGAR ↗